Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2023/08/056905
CTRI/2023/08/056905
Recruiting
Phase 4

A prospective, single-arm, multicenter, observationalsafety surveillance study of VyndaMx® (Tafamidiscapsule 61 mg) in patients with Transthyretin amyloidcardiomyopathy (ATTR-CM) in India - NI

Pfizer Products India Private Limited0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
Pfizer Products India Private Limited
Status
Recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Pms

Investigators

Sponsor
Pfizer Products India Private Limited

Eligibility Criteria

Inclusion Criteria

  • •Adult patients aged 18 years and more with diagnosis of cardiomyopathy of wild type or hereditary transthyretin mediated amyloidosis and Patients to whom VyndaMx Capsules is prescribed for the treatment of ATTR\-CM.

Exclusion Criteria

  • •Patient with hypersensitivity to VyndaMx® Capsule or to any of the excipients in the product
  • •Patients with rare hereditary problems of fructose intolerance.
  • •Patient who has a contraindication to VyndaMx® Capsules according to the approved local product label.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 4
Post Marketinng Surveillance to Evaluate implant survivorship and performance of the Freedom® Total Knee System in Total Knee ArthroplastyHealth Condition 1: M179- Osteoarthritis of knee, unspecified
CTRI/2016/11/007455Meril Life Sciences India Pvt Ltd400
Not yet recruiting
Phase 4
MITSU AB™ absorbable poly (glycolide/L-lactide) surgical suture U.S.P withantibacterial triclosan coatingHealth Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue
CTRI/2024/08/071764Meril Life Sciences Pvt Ltd
Recruiting
Not Applicable
OptimalCare StudyStable anginaStable angina, Chronic coronary syndromes, Coronary artery diseaseD060050
JPRN-jRCT1040230051Kinoshita Yoshihisa200
Not yet recruiting
Not Applicable
A prospective, single-arm, multicenter, investigator-initiated, interventional study to evaluate the efficacy and safety of switching from low- and moderate-intensity statin to Ezetimibe 10 mg and ROsuvastatIn 2.5 mg CombinAtion therapy in patients with type 2 diabetes mellitus with dyslipidemia. (EROICA)
KCT0008224Hanyang University Guri Hospital665
Recruiting
Not Applicable
Multicenter prospective cohort study to evaluate renal tubular function after switching from ETV to TAF - Niigata University study group
JPRN-UMIN000042929niigata university50